Publications by authors named "C Ellershaw"
Purpose: MMT95 was the fourth of a series of International Society of Pediatric Oncology (SIOP) collaborations for children with high-risk nonmetastatic soft tissue sarcoma (STS). The principal objective was to explore survival advantage for an intensified chemotherapy strategy in a randomized trial.
Patients And Methods: From July 1995 to June 2003, 457 previously untreated patients with incompletely resected embryonal rhabdomyosarcoma (RMS), undifferentiated sarcoma, and soft tissue primitive neuroectodermal tumor at all sites except paratesticular, vagina, and uterus, or with alveolar RMS were randomly assigned to receive either ifosfamide, vincristine, and dactinomycin (IVA) or a six-drug combination (IVA plus carboplatin, epirubicin, and etoposide) both delivered over 27 weeks.
Purpose: Results are presented of the SIOP study MMT-98 for paediatric metastatic rhabdomyosarcoma (RMS), which evaluated intensive chemotherapy followed by low intensity 'maintenance' chemotherapy in standard risk patients (SRG). For poor risk patients (PRG), the value of a therapeutic window study, sequential high dose monotherapy to achieve a complete response (CR) followed by low dose maintenance chemotherapy was examined.
Patients And Methods: From November 1998 to 2005, 146 patients aged 6 months to 18 years with metastatic RMS were entered.
Purpose: Carboplatin and etoposide are commonly used chemotherapeutics for the treatment of many paediatric cancers. However, there are very limited published data concerning the pharmacokinetics of these agents in infants and very young children, for whom dose reductions are frequently implemented.
Methods: Etoposide (5 mg/kg; 2 h i.
Purpose: On the assumption that most infants with disseminated neuroblastoma without MYCN amplification (MYCNA) have a favorable prognosis, two concomitant prospective trials were started in which chemotherapy was limited to patients presenting life- or organ-threatening symptoms or overt metastases to skeleton, lung, or CNS. Surgery was to be performed only in the absence of surgical risk factors.
Patients And Methods: One hundred seventy infants with disseminated neuroblastoma without MYCNA, diagnosed between June 1999 and June 2004 in nine European countries were eligible for either of the two studies.
Article Synopsis
- The study aimed to compare the effectiveness of an intensive chemotherapy protocol with a 10-day treatment interval against the standard protocol with a 21-day interval for high-risk neuroblastoma patients aged 1 year or older.
- Between 1990 and 1999, 262 patients were randomly assigned to either the rapid treatment (COJEC) or the standard treatment (OPEC/OJEC) regimens, both using similar total drug doses but differing in dose intensity and timing.
- The primary endpoints evaluated were event-free survival (EFS) at 3, 5, and 10 years, with responses assessed based on the International Neuroblastoma Response Criteria (INRC).